Bicara Therapeutics Inc. (BCAX)
Data as of , from SEC Form 4 filings.
Net insider selling (90d)Watch BCAX
See up to 3 months of BCAX. The 7-day demo opens the 1M and 3M ranges and puts BCAX on your watchlist.
Start 7-day demoLatest BCAX insider trades
Ryan Cohlhepp - OfficerOpen-market sale$320K- Ryan Cohlhepp - Officer
About Bicara Therapeutics Inc. (BCAX)
Bicara Therapeutics Inc. is an SEC registrant, filing under CIK 0002023658, classified as pharmaceutical preparations. It is grouped with Health Care companies on this site.
BCAX Form 4 activity by transaction type, last 90 days
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market sale | 5 | 58,750 | $1.55M |
| Grant or award | 3 | 362,900 | |
| Option exercise | 8 | 117,500 |
Dollar totals cover purchases and sales only (codes P and S). Grants, option exercises, gifts and tax withholding are counted in shares, because none of them is a trade at a market price.
BCAX insider transactions (Form 4)
11460 Form 4 filings on record, the earliest from Jun 9, 2025, newest first. Filing history page 2 of 2.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Claire Mazumdar - Officer | Option exercise | Stock Option (Right to Buy) | 3,817 | $0.00 | - | |
| Claire Mazumdar - Officer | Option exercise | Common Stock | 2,631 | $3.79 | $10K | |
| Claire Mazumdar - Officer | Open-market sale | Common Stock | 2,631 | $18.73 footnote F2 | $49K | |
| Claire Mazumdar - Officer | Option exercise | Common Stock | 1,786 | $3.79 | $7K | |
| Claire Mazumdar - Officer | Open-market sale | Common Stock | 1,786 | $18.74 footnote F3 | $33K | |
| Claire Mazumdar - Officer | Option exercise | Common Stock | 3,817 | $3.79 | $14K | |
| Claire Mazumdar - Officer | Open-market sale | Common Stock | 3,817 | $18.75 footnote F4 | $72K | |
| Claire Mazumdar - Officer | Option exercise | Stock Option (Right to Buy) | 2,631 | $0.00 | - | |
| Claire Mazumdar - Officer | Option exercise | Stock Option (Right to Buy) | 1,786 | $0.00 | - | |
| ||||||
| Ryan Cohlhepp - Officer | Open-market sale | Common Stock | 4,500 | $18.16 footnote F2 | $82K | |
| Ryan Cohlhepp - Officer | Option exercise | Stock Option (Right to Buy) | 12,892 | $0.00 | - | |
| Ryan Cohlhepp - Officer | Option exercise | Common Stock | 12,892 | $3.79 | $49K | |
| Ryan Cohlhepp - Officer | Open-market sale | Common Stock | 12,892 | $18.16 footnote F2 | $234K | |
| ||||||
 Ivan Hyep - Officer | Option exercise | Common Stock | 2,963 | $3.79 | $11K | |
| Ivan Hyep - Officer | Open-market sale | Common Stock | 2,963 | $18.25 footnote F3 | $54K | |
| Ivan Hyep - Officer | Option exercise | Stock Option (Right to Buy) | 7,318 | $0.00 | - | |
| Ivan Hyep - Officer | Option exercise | Stock Option (Right to Buy) | 6,237 | $0.00 | - | |
| Ivan Hyep - Officer | Option exercise | Stock Option (Right to Buy) | 2,963 | $0.00 | - | |
| Ivan Hyep - Officer | Option exercise | Common Stock | 7,318 | $3.79 | $28K | |
| Ivan Hyep - Officer | Option exercise | Common Stock | 6,237 | $3.79 | $24K | |
| Ivan Hyep - Officer | Open-market sale | Common Stock | 13,555 | $18.22 footnote F2 | $247K | |
| ||||||
 David Raben - Officer | Option exercise | Common Stock | 16,300 | $3.79 | $62K | |
| David Raben - Officer | Open-market sale | Common Stock | 16,300 | $18.52 footnote F2 | $302K | |
| David Raben - Officer | Option exercise | Stock Option (Right to Buy) | 200 | $0.00 | - | |
| David Raben - Officer | Option exercise | Stock Option (Right to Buy) | 16,300 | $0.00 | - | |
| David Raben - Officer | Option exercise | Common Stock | 200 | $3.79 | $758 | |
| David Raben - Officer | Open-market sale | Common Stock | 200 | $18.45 | $4K | |
| ||||||
| RA CAPITAL MANAGEMENT, L.P. | Open-market purchase | Common Stock | 300,000 | $16.00 | $4.80M | |
| RA CAPITAL MANAGEMENT, L.P. | Open-market purchase | Pre-Funded Warrant (Right to Buy) | 2,200,000 | $16.00 | $35.20M | |
| Ryan Cohlhepp - Officer | Option exercise | Common Stock | 3,108 | $3.79 | $12K | |
| Ryan Cohlhepp - Officer | Open-market sale | Common Stock | 3,108 | $18.04 footnote F2 | $56K | |
| Ryan Cohlhepp - Officer | Open-market sale | Common Stock | 523 | $18.04 footnote F2 | $9K | |
| Ryan Cohlhepp - Officer | Option exercise | Stock Option (Right to Buy) | 3,108 | $0.00 | - | |
| ||||||
| Ryan Cohlhepp - Officer | Grant or award | Stock Option (Right to Buy) | 300,000 | $0.00 | - | |
| Claire Mazumdar - Officer | Grant or award | Stock Option (Right to Buy) | 450,000 | $0.00 | - | |
| David Raben - Officer | Grant or award | Stock Option (Right to Buy) | 100,000 | $0.00 | - | |
| Ivan Hyep - Officer | Grant or award | Stock Option (Right to Buy) | 125,000 | $0.00 | - | |
 Lara Meisner - Officer | Grant or award | Stock Option (Right to Buy) | 90,000 | $0.00 | - | |
| Ryan Cohlhepp - Officer | Open-market sale | Common Stock | 3,828 | $18.10 footnote F2 | $69K | |
| ||||||
| Ivan Hyep - Officer | Option exercise | Common Stock | 1,882 | $3.79 | $7K | |
| Ivan Hyep - Officer | Open-market sale | Common Stock | 1,882 | $18.15 footnote F2 | $34K | |
| Ivan Hyep - Officer | Option exercise | Stock Option (Right to Buy) | 1,882 | $0.00 | - | |
| ||||||
| Ryan Cohlhepp - Officer | Open-market sale | Common Stock | 149 | $18.02 | $3K | |
| Ryan Cohlhepp - Officer | Option exercise | Common Stock | 8,000 | $3.79 | $30K | |
| Ryan Cohlhepp - Officer | Open-market sale | Common Stock | 8,000 | $18.68 footnote F2 | $149K | |
| Ryan Cohlhepp - Officer | Open-market sale | Common Stock | 4,500 | $18.68 footnote F2 | $84K | |
| Ryan Cohlhepp - Officer | Option exercise | Stock Option (Right to Buy) | 8,000 | $0.00 | - | |
| ||||||
| David Raben - Officer | Option exercise | Common Stock | 5,500 | $3.79 | $21K | |
| David Raben - Officer | Open-market sale | Common Stock | 5,500 | $18.45 | $101K | |
| David Raben - Officer | Option exercise | Common Stock | 4,594 | $3.79 | $17K | |
| David Raben - Officer | Open-market sale | Common Stock | 4,594 | $18.84 footnote F2 | $87K | |
| David Raben - Officer | Option exercise | Common Stock | 906 | $3.79 | $3K | |
| David Raben - Officer | Open-market sale | Common Stock | 906 | $18.84 footnote F2 | $17K | |
| David Raben - Officer | Option exercise | Stock Option (Right to Buy) | 5,500 | $0.00 | - | |
| David Raben - Officer | Option exercise | Stock Option (Right to Buy) | 4,594 | $0.00 | - | |
| David Raben - Officer | Option exercise | Stock Option (Right to Buy) | 906 | $0.00 | - | |
| ||||||
| Claire Mazumdar - Officer | Option exercise | Common Stock | 41,163 | $3.79 | $156K | |
| Claire Mazumdar - Officer | Open-market sale | Common Stock | 41,163 | $18.86 footnote F2 | $776K | |
| Claire Mazumdar - Officer | Option exercise | Stock Option (Right to Buy) | 41,163 | $0.00 | - | |
| ||||||
| Ivan Hyep - Officer | Option exercise | Common Stock | 605 | $3.79 | $2K | |
| Ivan Hyep - Officer | Open-market sale | Common Stock | 605 | $18.15 | $11K | |
| Ivan Hyep - Officer | Option exercise | Common Stock | 17,795 | $3.79 | $67K | |
| Ivan Hyep - Officer | Open-market sale | Common Stock | 17,795 | $18.55 footnote F2 | $330K | |
| Ivan Hyep - Officer | Option exercise | Stock Option (Right to Buy) | 605 | $0.00 | - | |
| Ivan Hyep - Officer | Option exercise | Stock Option (Right to Buy) | 17,795 | $0.00 | - | |
| ||||||
| Ryan Cohlhepp - Officer | Option exercise | Common Stock | 8,000 | $3.79 | $30K | |
| Ryan Cohlhepp - Officer | Open-market sale | Common Stock | 8,000 | $18.05 footnote F2 | $144K | |
| Ryan Cohlhepp - Officer | Open-market sale | Common Stock | 4,500 | $18.05 footnote F2 | $81K | |
| Ryan Cohlhepp - Officer | Option exercise | Stock Option (Right to Buy) | 8,000 | $0.00 | - | |
| ||||||
| Claire Mazumdar - Officer | Option exercise | Stock Option (Right to Buy) | 24,103 | $0.00 | - | |
| Claire Mazumdar - Officer | Option exercise | Common Stock | 24,103 | $3.79 | $91K | |
| Claire Mazumdar - Officer | Open-market sale | Common Stock | 24,103 | $18.83 footnote F2 | $454K | |
| ||||||
| Ryan Cohlhepp - Officer | Option exercise | Common Stock | 8,000 | $3.79 | $30K | |
| Ryan Cohlhepp - Officer | Open-market sale | Common Stock | 8,000 | $18.16 footnote F2 | $145K | |
| Ryan Cohlhepp - Officer | Open-market sale | Common Stock | 4,500 | $18.16 footnote F2 | $82K | |
| Ryan Cohlhepp - Officer | Option exercise | Stock Option (Right to Buy) | 8,000 | $0.00 | - | |
| ||||||
| Claire Mazumdar - Officer | Option exercise | Common Stock | 11,445 | $3.79 | $43K | |
| Claire Mazumdar - Officer | Open-market sale | Common Stock | 11,445 | $18.92 footnote F2 | $217K | |
| Claire Mazumdar - Officer | Option exercise | Common Stock | 13,289 | $3.79 | $50K | |
| Claire Mazumdar - Officer | Open-market sale | Common Stock | 13,289 | $18.84 footnote F3 | $250K | |
| Claire Mazumdar - Officer | Option exercise | Stock Option (Right to Buy) | 11,445 | $0.00 | - | |
| Claire Mazumdar - Officer | Option exercise | Stock Option (Right to Buy) | 13,289 | $0.00 | - | |
| ||||||
| David Raben - Officer | Option exercise | Common Stock | 22,000 | $3.79 | $83K | |
| David Raben - Officer | Open-market sale | Common Stock | 22,000 | $18.45 | $406K | |
| David Raben - Officer | Option exercise | Stock Option (Right to Buy) | 22,000 | $0.00 | - | |
| Ivan Hyep - Officer | Option exercise | Common Stock | 6,415 | $3.79 | $24K | |
| Ivan Hyep - Officer | Open-market sale | Common Stock | 6,415 | $18.23 footnote F2 | $117K | |
| Ivan Hyep - Officer | Option exercise | Stock Option (Right to Buy) | 6,415 | $0.00 | - | |
| ||||||
| Ivan Hyep - Officer | Option exercise | Common Stock | 6,514 | $3.79 | $25K | |
| Ivan Hyep - Officer | Open-market sale | Common Stock | 6,514 | $18.17 footnote F2 | $118K | |
| Ivan Hyep - Officer | Option exercise | Common Stock | 18,244 | $3.79 | $69K | |
| Ivan Hyep - Officer | Open-market sale | Common Stock | 18,244 | $18.22 footnote F3 | $332K | |
| Ivan Hyep - Officer | Option exercise | Common Stock | 5,627 | $3.79 | $21K | |
| Ivan Hyep - Officer | Open-market sale | Common Stock | 5,627 | $18.21 footnote F3 | $102K | |
| Ivan Hyep - Officer | Option exercise | Stock Option (Right to Buy) | 6,514 | $0.00 | - | |
| Ivan Hyep - Officer | Option exercise | Stock Option (Right to Buy) | 18,244 | $0.00 | - | |
| Ivan Hyep - Officer | Option exercise | Stock Option (Right to Buy) | 5,627 | $0.00 | - | |
| ||||||
| Ryan Cohlhepp - Officer | Option exercise | Common Stock | 24,000 | $3.79 | $91K | |
| Ryan Cohlhepp - Officer | Open-market sale | Common Stock | 24,000 | $18.06 footnote F2 | $433K | |
| Ryan Cohlhepp - Officer | Open-market sale | Common Stock | 15,600 | $18.06 footnote F2 | $282K | |
| Ryan Cohlhepp - Officer | Option exercise | Common Stock | 8,000 | $3.79 | $30K | |
| Ryan Cohlhepp - Officer | Open-market sale | Common Stock | 8,000 | $18.06 footnote F3 | $144K | |
| Ryan Cohlhepp - Officer | Open-market sale | Common Stock | 2,900 | $18.06 footnote F3 | $52K | |
| Ryan Cohlhepp - Officer | Option exercise | Stock Option (Right to Buy) | 24,000 | $0.00 | - | |
| Ryan Cohlhepp - Officer | Option exercise | Stock Option (Right to Buy) | 8,000 | $0.00 | - | |
| ||||||
| Lara Meisner - Officer | Option exercise | Common Stock | 33,807 | $9.24 | $312K | |
| Lara Meisner - Officer | Open-market sale | Common Stock | 33,807 | $14.75 | $499K | |
| Lara Meisner - Officer | Option exercise | Stock Option (Right to Buy) | 33,807 | $0.00 | - | |
| Lara Meisner - Officer | Option exercise | Common Stock | 15,829 | $5.45 | $86K | |
| Lara Meisner - Officer | Open-market sale | Common Stock | 15,829 | $11.49 | $182K | |
| Lara Meisner - Officer | Option exercise | Stock Option (Right to Buy) | 6,085 | $0.00 | - | |
| Lara Meisner - Officer | Option exercise | Stock Option (Right to Buy) | 9,744 | $0.00 | - | |
| Nils Lonberg - Director | Grant or award | Stock Option (Right to Buy) | 23,746 | $0.00 | - | |
| Michael Powell - Director | Grant or award | Stock Option (Right to Buy) | 23,746 | $0.00 | - | |
Item 1.01, 9.01
Item 2.02, 9.01
Item 5.02, 7.01, 9.01
Item 5.07
Recent BCAX Form 144 notices of proposed sale
3An insider files Form 144 before selling restricted or control stock. It announces a planned sale. If the sale goes ahead, it shows up later on a Form 4.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| Cohlhepp Ryan | Officer, Director | 17,500 | $396K | View on EDGAR | |
| Hyep Ivan | Officer | 12,500 | $283K |
BCAX insider trading FAQ
What is the latest insider trade for BCAX?
Bicara Therapeutics Inc. (BCAX) had 7 insider filings in the last 90 days, with the most recent on 2026-09-10. The full record for BCAX runs to 60 Form 4 filings, the earliest from 2025-06-09. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying BCAX stock?
No insider purchases of BCAX were filed in the last 90 days. 2 purchases are on record for this company.
How many insiders are selling BCAX stock?
5 insider sales of BCAX were filed in the last 90 days, totaling $1.55M.
Where can I see BCAX SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects BCAX Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
10The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - Ryan Cohlhepp view on EDGAR
- - Jennifer Larson view on EDGAR
- - Ivan Hyep view on EDGAR
- - Claire Mazumdar view on EDGAR
- - Ryan Cohlhepp view on EDGAR
- - Jeremy Bender view on EDGAR
- - Christy J. Oliger view on EDGAR
- - Claire Mazumdar view on EDGAR
- - Ryan Cohlhepp view on EDGAR
Related companies with recent insider activity
Learn more
- Insider selling: signal or noise?
- Why most insider sales are routine, and the few patterns worth a second look.
- Form 144 vs Form 4
- A Form 144 announces a planned sale; the Form 4 reports it after it happens.
- Insider activity in Health Care
- Where BCAX's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow BCAX with a 7-day demo
- BCAX on your watchlist
- Every BCAX Form 4 filing on record
- Up to 3 months of BCAX price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive
Start 7-day demoCard required. Your card is never charged for the demo.
